Response: In our report (1) , we demonstrated that IL-13 is a critical effector molecule in the allergic airway response. Although a number of investigators have shown that IL-13 is overexpressed in the lungs of asthmatic individuals, little is known about the underlying mechanisms governing IL-13 overexpression (2) . Possible mechanisms include polymorphisms in the gene itself, coordinate regulation of IL-13 gene expression by other cytokines or factors as yet undescribed, and polymorphisms in downstream receptor and signaling molecules. Several groups of investigators have shown linkage of asthmatic symptoms to regions of human chromosome 5q31-33, which encode genes for a number of cytokines including IL-13, IL-4, IL-3, IL-9, granulocyte-macrophage-colony-stimulating factor, IL-12B, and IL-5 (3). Several years ago, these genes were examined for sequence variants within a population of asthmatic individuals from families that had been collected and ascertained for asthma. The results of our findings, examining in detail the 5Ј region of gene structure for these seven cytokine genes, revealed significant populationbased promoter polymorphisms within the cytokine genes for IL-3, IL-4, and IL-9 (4). Our examination of similar 5Ј regions with putative promoter activity for all the other cytokine genes, including IL-13, yielded no significant population-based polymorphisms (5). Our studies included heteroduplex analysis via single-stranded conformation polymorphisms followed by sequencing of variants.
Other areas within the coding or intronic areas as well as the 3Ј areas of these cytokine genes remain potential candidates for identifying polymorphisms and, in fact, in a number of the genes in which no 5Ј or promoter polymorphisms were identified, or other structural and intronic polymorphisms have been identified. Furthermore, variation in the expression of some of these cytokine genes may be dependent not only on promoterbased regulation, but also on message stability, coordinate activation and regulation by common transactivators such as transcription factors.
We agree with Anderson, Mathieson, and Gillespie that the IL-13 promoter as a susceptibility locus is not a likely target for genetic control, but other important targets may exist that can provide genetic variation to the expression of IL-13, including coordinate regulation from other cytokines such as IL-4 and IL-9, as well as genetic variations in downstream receptor (IL-4Ra) and signaling molecules such as Janus-activated kinase 1 and 3 (JAK1 and 3) and STAT6. The relation of molecular variants in gene structure to asthma, atopy, or any disease must be confirmed by biologic function in vivo and in vitro and by association in population studies for these changes to be considered as disease modifying markers (6 ).
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